Global Digital Biomarker Market Strategic Research Report

Scope of the Report

The global Digital Biomarker market size is predicted to grow from US$ 3,724 million in 2025 to US$ 225,140 million in 2032; it is expected to grow at a CAGR of 80.6% from 2026 to 2032.

Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected and measured by means of digital devices such as portables, wearables, implantables, or digestibles. The data collected are typically used to explain, influence, and/or predict health-related outcomes. Digital biomarkers also represent an opportunity to capture clinically meaningful, objective data.

Digital biomarkers refer to biomedical data collected and analyzed through digital technology, which are used to detect, monitor and predict disease biomarkers. These data are usually collected through technologies such as smart devices, wearable sensors, and mobile applications, including physiological data such as heart rate, gait, blood sugar, brain waves, and sleep patterns. In recent years, with the rapid development of technologies such as artificial intelligence, big data analysis, and the Internet of Things (IoT), digital biomarkers have gradually shown great potential in disease diagnosis, efficacy evaluation, and health management.

At present, the digital biomarker market is in a rapid development stage. The popularity of digital health devices and the demand for personalized medicine and precision medicine have promoted the research and application of digital biomarkers. In the early diagnosis and monitoring of some chronic disease management and neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), digital biomarkers have shown significant application value. In addition, digital biomarkers are also playing an increasingly important role in the drug development process, especially in the recruitment of patients in clinical trials, monitoring of treatment effects, and evaluation of side effects.

In the future, digital biomarkers are expected to be more widely used in multiple fields. First, with the continuous advancement of artificial intelligence and machine learning algorithms, the analytical capabilities of digital biomarkers will become more accurate and efficient, which will help to formulate more personalized treatment plans. Secondly, with the popularization of 5G technology, the improvement of real-time data transmission capabilities will enable digital biomarkers to monitor patients' health status in real time and increase the possibility of early detection of diseases. In addition, cross-industry cooperation and standardization of digital biomarkers will also promote their widespread application around the world.

Philips and Novartis are the top 2 companies in global digital biomarker market and account for over 15% of total market share. Geographically speaking, Europe holds about 45% of global market share, followed by North America with about 35% share. In terms of type, passive digital biomarker segment holds an important share of about 65%. In terms of application, clinical disease segment accounts for about 80% of the total share.

This report presents a comprehensive overview of the global Digital Biomarker market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Passive Digital Biomarker
• Active Digital Biomarker

Segment by players, this report covers

• Philips
• Johnson & Johnson
• Pfizer
• GE Healthcare
• Novartis
• Apple
• Sanofi
• GlaxoSmithKline
• Bayer
• Merck
• Abbott Laboratories
• Asahi Kasei
• Biogen
• Koneksa Health
• Roche
• Huma Therapeutics

Segment by Application

• Clinical Disease
• Daily Health

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Digital Biomarker market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Clinical Disease, Daily Health evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact